BIOMARKER-DRIVEN LUNG CANCER

>

Latest News

Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment
Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment

February 19th 2024

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC
FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC

January 19th 2024

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC
Evaluating the TKI Inhibitors in Fusion-Driven NSCLC

January 5th 2024

FDA Places Clinical Hold on Trial of LN-45 in NSCLC
FDA Places Clinical Hold on Trial of LN-45 in NSCLC

January 4th 2024

More News